[go: up one dir, main page]

MX9603859A - Producto y proceso para la regulacion de celulas t. - Google Patents

Producto y proceso para la regulacion de celulas t.

Info

Publication number
MX9603859A
MX9603859A MX9603859A MX9603859A MX9603859A MX 9603859 A MX9603859 A MX 9603859A MX 9603859 A MX9603859 A MX 9603859A MX 9603859 A MX9603859 A MX 9603859A MX 9603859 A MX9603859 A MX 9603859A
Authority
MX
Mexico
Prior art keywords
mhc
linker
peptide
disclosed
antigenic peptide
Prior art date
Application number
MX9603859A
Other languages
English (en)
Other versions
MXPA96003859A (es
Inventor
John W Kappler
Philippa Marrack
Original Assignee
Nat Jewish Ct For Immunology A
Respiratory Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nat Jewish Ct For Immunology A, Respiratory Medicine filed Critical Nat Jewish Ct For Immunology A
Publication of MX9603859A publication Critical patent/MX9603859A/es
Publication of MXPA96003859A publication Critical patent/MXPA96003859A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/795—Porphyrin- or corrin-ring-containing peptides
    • C07K14/80—Cytochromes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/77—Ovalbumin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/30—Animal model comprising expression system for selective cell killing, e.g. toxins, enzyme dependent prodrug therapy using ganciclovir
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0306—Animal model for genetic diseases
    • A01K2267/0325—Animal model for autoimmune diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)

Abstract

La presente invencion se refiere a un producto y proceso para regular la actividad de las células T usando complejos de histocompatibilidad mayor (MHC) enlazados de manera estable con péptidos antigénicos. Se describe un péptido antigénico enlazado de forma covalente a una proteína de complejo de histocompatibilidad mayor (MHC) mediante un enlazador novedoso, permitiendo de este modo la formacion de un complejo de péptido-MHC estable, solo o en combinacion con cadenas adicionales de proteína de complejo de histocompatibilidad mayor capaces de ser reconocidas por un receptor de célula T (TCR). También se describe una molécula nucleica que tiene una secuencia que codifica a una molécula de Péptido-L-MHC que comprende un péptido antigénico unido mediante un enlazador a un segmento de complejo de histocompatibilidad mayor. La invencion está dirigida adicionalmente a las formulaciones que comprenden un péptido antigénico unido mediante un enlazador a un segmento de complejo de histocompatibilidad mayor anclado en un sustrato que contiene un lípido. También se describen reactivos farmacéuticos que contienen un pépetido antigénico unido mediante un enlazador a un segmento de complejo de histocompatibilidad mayo combinado con un vehículo adecuado que es capaz de presentar la molécula del péptido-L-MHC de modo que es capaz de ser reconocida.de Célula-T.
MXPA/A/1996/003859A 1994-03-04 1996-09-04 Producto y proceso para la regulacion de celulas t MXPA96003859A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08207481 1994-03-04
US08/207,481 US5820866A (en) 1994-03-04 1994-03-04 Product and process for T cell regulation
PCT/US1995/002689 WO1995023814A1 (en) 1994-03-04 1995-03-03 Product and process for t cell regulation

Publications (2)

Publication Number Publication Date
MX9603859A true MX9603859A (es) 1997-07-31
MXPA96003859A MXPA96003859A (es) 1997-12-01

Family

ID=

Also Published As

Publication number Publication date
KR100376544B1 (ko) 2003-06-12
WO1995023814A1 (en) 1995-09-08
AU2094295A (en) 1995-09-18
JPH09509944A (ja) 1997-10-07
CA2184810A1 (en) 1995-09-08
JP2006094862A (ja) 2006-04-13
US5820866A (en) 1998-10-13

Similar Documents

Publication Publication Date Title
Williams et al. The events of primary T cell activation can be staged by use of Sepharose-bound anti-T3 (64.1) monoclonal antibody and purified interleukin 1.
CA2212747A1 (en) Mhc-antigen complexes for detecting and purifying antigen-specific t cells
Jung et al. Human T lymphocytes recognize a peptide of single point-mutated, oncogenic ras proteins.
Martin et al. T cell recognition of haptens, a molecular view
EP0997477A3 (en) MHC complexes and uses thereof
Cavani et al. Characterization of epitopes recognized by hapten-specific CD4+ T cells.
CA2290485A1 (en) Method for the production of non-immunogenic proteins
EP1526141A3 (en) MHC complexes and uses thereof
DE69632815D1 (de) gC1q-REZEPTOR, DARAN BINDENDE HIV-1 gp120-REGION, VERWANDTE PEPTIDE UND ANTIKÖRPER
EP0845032A3 (en) Isolated nucleic acid molecules, peptides which form complexes with mhc molecule hla-a2 and uses thereof
IL152886A0 (en) B-7 related nucleic acids and polypeptides and pharmaceutical compositions containing the same
ZA952375B (en) Isolated tumor rejection antigen precursor mage-2 derived peptides and uses thereof
SI1549750T1 (sl) Modularne antigen transportne molekule (MAT-molekule) za moduliranje imunskih reakcij, z njimi povezani konstrukti, postopki in uporabe
ATE207459T1 (de) O-malonyltyrosyl-verbindungen, o-malonyltyrosyl- verbindungen enthaltende peptide und ihre verwendung
BR0012038A (pt) Molécula de ácido nucleico isolada, vetor, célula hospedeira, polopeptìdeo, proteìna, e, métodos para produzir um polipeptìdeo, para produzir um produto quìmico fino, e, de diagnosticar a presença ou atividade de corybacterium diphotheriae em um paciente
BR9707589A (pt) Proteìna hìbrida, molécula de dna, vetor de expressão, célula hospedeira, composição farmacêutica e processos para produzir proteìna hìbrida e para induzir maturação folicular.
NZ333203A (en) Tumour antigen proteins, genes thereof, and tumour antigen peptides
Bierlmeier et al. Sortase‐Mediated Multi‐Fragment Assemblies by Ligation Site Switching
Tso et al. Primary structure of Serratia marcescens anthranilate synthase component II.
MX9603859A (es) Producto y proceso para la regulacion de celulas t.
CA2301709A1 (en) Epitope-bearing major histocompatibility complex class ii element/immunoglobulin chimeric molecules
Hampl et al. In vitro processing of insulin for recognition by murine T cells results in the generation of A chains with free CysSH
ATE336579T1 (de) Isolierte mhc-klasse ii-bindende peptide, und deren verwendung
Weng et al. Amino acid sequence at the allosteric site of sheep heart phosphofructokinase.
Kropshofer et al. Evidence for cobinding of self-and allopeptides to human class II major histocompatibility antigen DR1 by energy transfer.

Legal Events

Date Code Title Description
FG Grant or registration
MM Annulment or lapse due to non-payment of fees